SURMOUNT-4 showed that stopping tirzepatide leads to regain, so plans for long-term therapy are necessary before starting [10]
glucagon suppression, lowering hepatic glucose output Central Nervous System: Decreases food intake by targeting homeostatic and hedonic appetite pathways (hindbrain/hypothalamus), reducing hunger and cravings, and enhancing satiety Gastrointestinal Tract: Delays gastric emptying, contributing to satiety (transient effect at higher doses) Adiposity/Energy Intake : Weight loss is primarily driven by sustained reduction in caloric intake, not increased energy expenditure Biological Activity Potent GLP-1 receptor agonist Enhances insulin secretion (glucose-dependent) Suppresses glucagon secretion Reduces appetite and caloric intake Produces significant, sustained body weight loss Improves cardiometabolic risk factors (glycemia, blood pressure, lipids) Storage Refrigerate once reconstituted
Morgan GE Jr, Mikhail MS, Murray MJ (Editors)
These medications, provided by Abundant Life Healthcare, share a common thread in that they all belong to the class of glucagon-like peptide-1 (GLP-1) receptor agonists
Meaning we can eat relatively large volumes of naturally satiating foods while painlessly achieving lower calorie intake
